Rob Dillard

DocwireNews

Cytogenic anomaly screening should be performed in every patient with chronic lymphocytic leukemia (CLL), according to a study presented at the SOHO 2024 Annual Meeting.In this retrospective study, researchers assessed 100 patients diagnosed with CLL who were between 18 and 80 years of age. The population of interest was followed in Erciyes University Faculty of Medicine, Hematology-Oncology Hospital between January 2010 and January 2022.The study found that over half (56%) of the patients were positive for any cytogenetic abnormality. The most common cytogenetic abnormality observed was 13q14 deletion, which was found to be positive in 40.3% of the patients. The study found 17p deletion to be positive in 17%, 11q deletion in 15.4%, and trisomy 12 in 12.5% of the patients. 17p and 11q deletions were associated with poor prognosis, the researchers noted.&ldquo;According to our findings, the presence of cytogenetic abnormalities has an important role in disease risk determination in accordance with the literature. Therefore, cytogenetic anomaly screening should be performed in every patient before treatment. This screening is important for determining the prognosis, stage, and treatment options,&rdquo; the researchers concluded.ReferenceGolbasi M, Unal A, Ozkul Y, Dundar M, Mandaci S, Akyol G, Keklik M. Frequency of Genetic Mutations in 
Patients With Chronic Lymphocytic Leukemia and Their Effects on Survival.&nbsp;Abstract #CLL-168. Presented at the Society of Hematologic Oncology Meeting 2024; September 4-7, 2024; Houston, Texas.

Sara Nunnery, MD, MSCI

Trastuzumab Deruxtecan in HER2-Low Breast Cancer: Who’s the Right Patient?

HER2 Breast Cancer

Meghan Sise, MD

Joel M. Topf, MD, FACP

Redefining Carboplatin Dosing

NKF Spring Clinical Meetings 2025

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Latest News

Cytogenetic Anomaly Screening is Necessary in CLL Patients Before Treatment

SOHO 2024: Focus on CLL

Cytogenic anomaly screening should be performed in every patient with CLL.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe